



(12) Translation of
European patent specification

(11) NO/EP 2542236 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/351 (2006.01)
A61P 9/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.03.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.10.26
(86)	European Application Nr.	11707324.7
(86)	European Filing Date	2011.03.01
(87)	The European Application's Publication Date	2013.01.09
(30)	Priority	2010.03.02, US, 309592 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Lexicon Pharmaceuticals, Inc., 8800 Technology Forest Place, The Woodlands, TX 77381, US-USA
(72)	Inventor	BROWN, Philip Manton, 3554 Rosedale Ave, DallasTX 75205, US-USA FREIMAN, Joel Philip, 27 Mistflower Place, The WoodlandsTexas 77381, US-USA POWELL, David Reed, 5327 Stillbrooke Road, HoustonTexas 77096, US-USA
(74)	Agent or Attorney	Håmsø Patentbyrå ANS, Postboks 171, 4301 SANDNES, Norge


(54)	Title	COMBINATIONS COMPRISING 6-BENZYLPHENYL-2- SULFURTERAHYDROPYRAN-3,4,5-TRIOL DERIVATIVES AS INHIBITORS OF SODIUM -GLUCOSE COTRANSPORTERS 1 AND 2 FOR USE IN DIABETIC PATIENTS
(56)	References Cited:	WO-A1-2010/009197 WO-A2-2008/042688 Lexicon Pharmaceuticals INC: "Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients", , 20 January 2010 (2010-01-20), XP002632758, Retrieved from the Internet: URL: http://www.news-medical.net/news/20100120/Lexicon-Pharmaceuticals-reports-positive-results-from-its-LX4211-Phase-2-trial-in-type-2-diabetic-patients.aspx [retrieved on 2011-04-04] "Study of LX4211 in subjects with type 2 diabetes mellitus (NCT00962065)", , 14 September 2009 (2009-09-14), XP002632802, Retrieved from the Internet: URL: https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_related_ref_to?p_id=636286&p_origen=PRO&p_tsearch=link [retrieved on 2011-04-14] KOMOROSKI B ET AL: "Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.", CLINICAL PHARMACOLOGY AND THERAPEUTICS MAY 2009 LNKD- PUBMED:19129749, vol. 85, no. 5, May 2009 (2009-05), pages 513-519, XP009146835, ISSN: 1532-6535 Freiman et al.: "LX4211, an SGLT2 Inhibitor, Shows Rapid and Significant Improvement in Glycemic Control over 4 Weeks inPatients with Type 2 Diabetes Mellitus.", , 22 June 2010 (2010-06-22), XP002632759, Retrieved from the Internet:

URL:<http://www.endojournals.org/abstracts/abstracts.dtl> [retrieved on 2011-04-04]
 Freiman et al.: "LX4211, an SGLT2 Inhibitor, Shows Improvements in Cardiovascular Risk Factors over 4 Weeks in Patients with Type 2 Diabetes Mellitus.", , 21 June 2010 (2010-06-21), XP002632760, Retrieved from the Internet: URL:<http://www.posters2view.com/endo/> [retrieved on 2011-04-04]
 FREIMAN J ET AL: "LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2 diabetes (T2DM)", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 59, no. suppl. 1, 25 June 2010 (2010-06-25), pages LB5-LB6, XP009146827, ISSN: 0012-1797
 "Study of LX4211 in subjects with type 2 diabetes mellitus", , 4 February 2011 (2011-02-04), XP002632803, Retrieved from the Internet: URL:<http://clinicaltrials.gov/ct2/show/results/NCT00962065?sect=X0125all> [retrieved on 2011-04-14]
 WASHBURN WILLIAM N: "Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 19, no. 11, 1 November 2009 (2009-11-01), pages 1485-1499, XP002593697, ISSN: 1354-3776, DOI: DOI:10.1517/13543770903337828
 Lexicon Pharmaceuticals: "LX4211", , 4 April 2011 (2011-04-04), XP002632761, Retrieved from the Internet: URL:<http://www.lexicon-genetics.com/pipeline/lx4211.html> [retrieved on 2011-04-04]
 John Doupis ET AL: "DPP4 Inhibitors: a new approach in diabetes treatment", Advances in Therapy, vol. 25, no. 7, 1 July 2008 (2008-07-01), pages 627-643, XP55071538, ISSN: 0741-238X, DOI: 10.1007/s12325-008-0076-1

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

P a t e n t k r a v

1. Dose på 300 mg/dag eller mindre (f.eks. 250, 200, 150, 100 eller 50 mg/dag eller mindre) av en dobbel SGLT1/2-hemmer med formelen:



eller et farmasøytisk akseptabelt salt derav, for anvendelse for å forbedre den kardiovas-
kulære eller metabolske helsen til en diabetisk eller pre-diabetisk pasient som tar en
DPP-4-hemmer, hvori:

hver R_{1A} er uavhengig hydrogen, alkyl, aryl eller heterosyklus;

hver R_6 er uavhengig hydrogen, hydroksyl, amino, alkyl, aryl, cyano, halogen, heteroalkyl,
heterosyklus, nitro, $C\equiv CR_{6A}$, OR_{6A} , SR_{6A} , SOR_{6A} , SO_2R_{6A} , $C(O)R_{6A}$, CO_2R_{6A} , CO_2H ,
 $CON(R_{6A})(R_{6A})$, $CONH(R_{6A})$, $CONH_2$, $NHC(O)R_{6A}$ eller $NHSO_2R_{6A}$;

hver R_{6A} er uavhengig alkyl, aryl eller heterosyklus;

hver R_7 er uavhengig hydrogen, hydroksyl, amino, alkyl, aryl, cyano, halogen, heteroalkyl,
heterosyklus, nitro, $C\equiv CR_{7A}$, OR_{7A} , SR_{7A} , SOR_{7A} , SO_2R_{7A} , $C(O)R_{7A}$, CO_2R_{7A} , CO_2H ,
 $CON(R_{7A})(R_{7A})$, $CONH(R_{7A})$, $CONH_2$, $NHC(O)R_{7A}$ eller $NHSO_2R_{7A}$;

hver R_{7A} er uavhengig alkyl, aryl eller heterosyklus;

m er 1-4;


n er 1-3;

p er 0-2; og


hvor hvert alkyl, aryl, heteroalkyl eller heterosyklus er valgfritt substituert med én eller fle-
re av alkoksy, amino, cyano, halo, hydroksyl, eller nitro, og hvori DPP-4-hemmeren er si-
tagliptin.

2. Dose for anvendelse ifølge krav 1, hvori forbedringen er en senkning av pasientens fas-
tende plasmaglukosenivå med mer enn 50, 55 eller 60 mg/dl.
3. Dose for anvendelse ifølge krav 1, hvori forbedringen er en senkning av pasientens
HbA1c-nivå med mer enn ca. 1,0, 1,1, eller 1,2 prosent


4. Dose for anvendelse ifølge krav 1, hvori forbedringen er en senkning av pasientens plasmafruktosaminnivå med mer enn ca. 30, 40, eller 50 $\mu\text{mol/l}$.
5. Dose for anvendelse ifølge krav 1, hvori forbedringen er en senkning av pasientens blodtrykk.
- 5 6. Dose for anvendelse ifølge krav 1, hvori forbedringen er en senkning av pasientens triglyseridnivåer.
7. Dose for anvendelse ifølge krav 1, hvori den doble SGLT1/2-hemmeren har formelen:



- 10 8. Dose for anvendelse ifølge krav 7, hvori den doble SGLT1/2-hemmeren har formelen:



9. Dose for anvendelse ifølge krav 8, hvori den doble SGLT1/2-hemmeren har formelen:



10. Dose for anvendelse ifølge krav 9, hvori R_{7A} er metyl eller etyl.
11. Dose for anvendelse ifølge krav 9, hvori R_{1A} er metyl.
12. Dose for anvendelse ifølge krav 11, hvori den doble SGLT1/2-hemmeren er (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol.